Latest market price
30.25
-0.73-2.36%
OverviewShort InterestFilings
VERAQT42Vera Therapeutics, Inc.·NASDAQ
30.25-2.36%
Earnings
Down 2.4% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
XNCR-0.54%$29.66HRMY-2.19%$37.91AUPH-3.06%$16.14RCUS-1.87%$17.85PVLA+0.12%$146.33BCRX-2.72%$8.24LKFT-0.81%$32.02ZYME+1.33%$28.99
Snapshot
Index—P/E—EPS (ttm)-5.86Insider Own—Shs Outstand72.06MPerf Week6.89%
Market Cap2.18BForward P/E—EPS next Y-4.27Insider Trans-0.56%Shs Float58.51MPerf Month-0.56%
Enterprise Value1.76BPEG—EPS next Q-1.62Short Float23.22%Perf Quarter1.00%
Income-401.00MP/S—EPS this Y—Short Ratio6.25Perf Half Y-14.81%
Sales0.00P/B5.34EPS next Y—ROA-75.40%Short Interest13.59MPerf YTD-40.26%
Book/sh5.66P/C4.37EPS next 5Y—ROE-84.13%52W High56.05 -46.03%Perf Year1.95%
Cash/sh6.92P/FCF—EPS past 3/5Y—ROIC-85.78%52W Low23.05 31.24%Perf 3Y195.70%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility5.97% 5.68%Perf 5Y73.35%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.78Perf 10Y—
Dividend Ex-Date—Quick Ratio10.92Sales Y/Y TTM—Profit Margin0.00%RSI (14)49.80Recom2.00
Dividend Gr. 3/5Y—Current Ratio10.92EPS Q/Q-26.67%SMA203.39%Beta1.12Target Price80.89
Payout0.00%Debt/Eq0.18Sales Q/Q—SMA50-5.35%Rel Volume1.01Prev Close30.98
Employees361LT Debt/Eq0.18EarningsNov 05SMA200-17.97%Avg Volume2.09MPrice30.25
IPO DateMay 14, 2021Option/ShortYes / YesEPS/Sales Surpr.3.54% —Net Debt/EBITDA—Volume2,111,134Change-2.36%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-12-26InitiatedLeerinkMarket Perform$34
Aug-11-26ReiteratedRaymond JamesStrong Buy$78 → $84
Jul-08-26ReiteratedNeedham
Jul-08-26ReiteratedHC Wainwright & Co.Buy$90
Jul-08-26ReiteratedGuggenheimBuy$76
Jul-08-26ReiteratedWedbushNeutral$33 → $43
Jun-02-26ReiteratedJefferiesBuy$6.00 → $60
Jun-02-26ReiteratedGoldman SachsBuy$95 → $90
May-15-26ReiteratedEvercore ISI GroupOutperform$97 → $91
Mar-11-26UpgradeWolfe ResearchPeer Perform → Outperform
Latest News· Times ET
Nov-02-26
Nov-02-2608:00AM
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conferenceglobenewswire.com
Oct-22-26
Oct-22-2609:04PM
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Resultsmarketbeat.com
07:17PM
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcriptseekingalpha.com
10:05AM
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicineglobenewswire.com
06:06AM
Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 WeeksBenzinga
Oct-20-26
Oct-20-2608:00AM
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcastglobenewswire.com
Oct-12-26
Oct-12-2604:22AM
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34Benzinga
Oct-09-26
Oct-09-2604:01AM
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga
Oct-02-26
Oct-02-2604:05PM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
09:24AM
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026globenewswire.com
05:28AM
Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA NephropathyBenzinga
Sep-24-26
Sep-24-2610:27AM
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?Yahoo
Sep-17-26
Sep-17-2601:58PM
2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be BrewingYahoo
Sep-15-26
Sep-15-2609:51PM
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch NextYahoo
08:01PM
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
Company

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A
0000————
Gross Profit
0000————
Selling, General and Administrative Excl. Other1531004124————
Research and Development26121512678————
Other Operating Expense
1000————
Operating Income-415-315-167-102————
Interest Expense8884————
Unusual Expense
————————
Non-Operating Income (Expense)22232310————
Net Income Before Taxes-401-300-152-96————
Income Taxes
0000————
Consolidated Net Income-401-300-152-96————
Net Income From Continuing Operations-401-300-152-96————
Net Income-401-300-152-96————
EPS (Recurring)-5.86-4.66-2.75-2.25————
EPS (Basic, Before Extraordinaries)-5.86-4.66-2.75-2.25————
EPS (Diluted)-5.86-4.66-2.75-2.25————
EBITDA-393-292-144-92————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding72645543————
Market Capitalization2,1783,2412,326661————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$60.82$49.66$38.51$27.35$16.19● Close Price0.00M0.98M1.96M2.93M3.91MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Sale37.0018,500684,500235,244Sep 17
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Option Exercise2.9018,50053,591253,744Sep 17
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRSep 11 '26Option Exercise3.945,00019,69880,754Sep 14
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Option Exercise2.9018,50053,591253,744Sep 04
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Sale35.1218,500649,642235,244Sep 04
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Sale42.3092,5003,912,374151,994Aug 12
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Option Exercise2.9046,250133,977281,494Aug 12
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Sale37.9337,0001,403,538198,244Aug 12
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Option Exercise2.9018,50053,591253,744Aug 12
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Option Exercise2.9018,50053,591253,744Aug 12
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Sale36.7437,0001,359,494216,744Aug 12
Fordyce MarshallPRESIDENT AND CEOApr 14 '26Sale44.0522,9511,011,051235,244Apr 15
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRMar 13 '26Option Exercise3.9410,00039,39675,754Mar 16
Brenner RobertChief Medical OfficerFeb 23 '26Sale41.982,15190,30750,947Feb 25
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRFeb 23 '26Sale41.983,117130,86464,722Feb 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.